- Home
- ANGH vs IMMX Comparison
ANGH vs IMMX Comparison
Compare ANGH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- IMMX
- Stock Information
- Founded
- ANGH 2012
- IMMX 2014
- Country
- ANGH United Arab Emirates
- IMMX United States
- Employees
- ANGH N/A
- IMMX N/A
- Industry
- ANGH Telecommunications Equipment
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- ANGH Consumer Discretionary
- IMMX Health Care
- Exchange
- ANGH Nasdaq
- IMMX Nasdaq
- Market Cap
- ANGH 47.5M
- IMMX 50.1M
- IPO Year
- ANGH N/A
- IMMX 2021
- Fundamental
- Price
- ANGH $0.67
- IMMX $1.75
- Analyst Decision
- ANGH
- IMMX Strong Buy
- Analyst Count
- ANGH 0
- IMMX 1
- Target Price
- ANGH N/A
- IMMX $7.00
- AVG Volume (30 Days)
- ANGH 27.0K
- IMMX 47.5K
- Earning Date
- ANGH 04-11-2025
- IMMX 05-08-2025
- Dividend Yield
- ANGH N/A
- IMMX N/A
- EPS Growth
- ANGH N/A
- IMMX N/A
- EPS
- ANGH N/A
- IMMX N/A
- Revenue
- ANGH $52,274,011.00
- IMMX N/A
- Revenue This Year
- ANGH N/A
- IMMX N/A
- Revenue Next Year
- ANGH N/A
- IMMX N/A
- P/E Ratio
- ANGH N/A
- IMMX N/A
- Revenue Growth
- ANGH 13.03
- IMMX N/A
- 52 Week Low
- ANGH $0.61
- IMMX $1.26
- 52 Week High
- ANGH $2.27
- IMMX $3.13
- Technical
- Relative Strength Index (RSI)
- ANGH 45.48
- IMMX 41.38
- Support Level
- ANGH $0.62
- IMMX $1.64
- Resistance Level
- ANGH $0.76
- IMMX $1.90
- Average True Range (ATR)
- ANGH 0.06
- IMMX 0.14
- MACD
- ANGH 0.00
- IMMX 0.00
- Stochastic Oscillator
- ANGH 37.53
- IMMX 10.44
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.